arrow
T

Thomas Seufferlein

ulm university
H指数:78
被引数:3.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy

患者来源类器官和患者来源异种移植作为预测抗肿瘤治疗反应的替身模型的比较分析

2026-07-160
OAAI
DKK3 Initially Preserves Acinar Integrity Through MEK-Fos Signaling, but Later Switches to an Oncogenic Role in Pancreatic Cancer

DKK3通过MEK-Fos信号通路最初保持腺泡完整性,但随后转变为在胰腺癌中的致癌作用。

2025-10-280
OAAI
Impact of preoperative radiotherapy on patient-reported outcomes in rectal cancer

术前放疗对直肠癌患者报告结局的影响

2025-07-100
PRE
Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment

结直肠癌患者治疗开始1年后自我报告的财务困难

2025-05-010
OAAI
Pain and overall quality of life in palliatively treated colorectal cancer patients 1 year after diagnosis- results from the EDIUM cohort

姑息治疗后的结直肠癌患者1年后疼痛与整体生活质量——EDIUM队列研究结果

2025-03-310
OA
Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts)

NEONAX试验的探索性生物标志物分析,用于预测可切除胰腺导管腺癌患者(rPDAC Pts)对围手术期(PO)和辅助性(A)Gem-nabPac化疗(CTX)的治疗反应

2024-09-010
PRE